Physician profile
Gary A Matusow
NPI 1033154463
$8,663.92
in general payments reported to CMS, 2019-2025
32 companies · $2,256 in 2025
The $2,256 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.65 · 2021: $592 · 2022: $2,212 · 2023: $1,643 · 2024: $1,905 · 2025: $2,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,654 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,654.43 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,159.41 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $801.89 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $664.02 | 2019-2025 | Xifaxan |
| Qol Medical, LLC | $660.55 | 2022-2025 | Sucraid, Sucraid |
| Celgene Corporation | $434.76 | 2022-2024 | Zeposia |
| Pfizer INC. | $402.00 | 2021-2025 | |
| Gilead Sciences, INC. | $369.41 | 2021-2025 | |
| Intra-Sana Laboratories | $346.93 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Biotech, INC. | $284.31 | 2022-2025 | Stelara, Simponi, Simponi Aria |
| Aimmune Therapeutics, INC. | $248.24 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $235.93 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $223.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $188.73 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $164.72 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $151.73 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $150.00 | 2023 | Tysabri |
| Novo Nordisk INC | $141.49 | 2023-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $139.18 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $138.93 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $137.99 | 2021-2023 | Injectafer |
| Pharmacosmos Therapeutics INC. | $135.59 | 2023 | Monoferric |
| Genzyme Corporation | $118.57 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.03 | 2024 | Zeposia |
| Redhill Biopharma INC. | $69.78 | 2021-2023 | Aemcolo, Talicia |
| Ferring Pharmaceuticals INC. | $52.90 | 2022 | |
| Valinor Pharma, LLC | $43.44 | 2024 | Movantik |
| Currax Pharmaceuticals LLC | $29.66 | 2021 | |
| Organon LLC | $26.76 | 2023 | Renflexis |
| Celltrion USA INC. | $18.71 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $18.50 | 2024 | |
| Alfasigma USA, INC. | $14.26 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Matusow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.